@drjoe_md's peptide FDA claims need context

What did @drjoe_md actually say?

The core argument here is that FDA approval is driven by patent economics, not just science. Pharmaceutical companies fund trials to own a market, and if a compound can't be patented, there's no return on investment. He uses BPC-157 and tesamorelin to illustrate both sides of that argument, and adds that "not FDA approved doesn't automatically mean they don't work or they're unsafe."

This is a fairly sophisticated point that doesn't oversell peptides. He's not claiming BPC-157 cures injuries or that you should inject TB-500 before your next workout. He's making a structural argument about drug development economics, which is a real and documented problem in pharmaceutical research. That's a more honest framing than most peptide content you'll find on TikTok, where vague claims about "healing" and "optimization" go completely unchallenged.

Does the science back this up?

Mostly, yes. The economics argument is well-supported, and the Supreme Court reference is real. The gaps are in what he left out, not what he said.

The 2013 Supreme Court case he references is Association for Molecular Pathology v. Myriad Genetics, which ruled that naturally occurring DNA sequences cannot be patented. He's applying this logic to peptides, and it holds in many cases, but it's an oversimplification. Patent law around peptides is genuinely complex. Synthetic modifications, novel delivery mechanisms, and specific formulations can still attract patent protection even for peptide-based compounds. The funding gap for unpatentable compounds is also well-documented. A 2011 analysis by Ridley, Grabowski, and Moe in Health Affairs showed that market exclusivity is the primary driver of pharmaceutical R&D investment, which directly supports his point. The problem is that "no one will fund it" is different from "it works but can't be proven." Absence of trials doesn't validate efficacy. It just means we don't know.

What did they get wrong (or right)?

He got the tesamorelin example right. It is FDA approved, specifically for HIV-associated lipodystrophy, and it does demonstrate that a peptide can clear the approval process when commercial exclusivity is achievable. Credit for that.

Where this gets shakier is the BPC-157 claim. He says it "comes from cells near the gut" and will "likely never be FDA approved." The origin description is loosely accurate, BPC-157 is derived from a sequence in gastric juice, but the leap to "it works but won't be approved because of patents" isn't supported by current evidence. Most BPC-157 research consists of rodent studies. A 2022 review by Gwyer, Bhatt, and Stanford in Current Pharmaceutical Design acknowledged preclinical promise but noted the near-total absence of human clinical trial data. Framing the approval gap primarily as an economics problem implies the compound has already proven itself. It hasn't, not in humans. That's a meaningful omission. He also skips over FDA's compounding regulations entirely, which is where most patients actually access these peptides, and that regulatory territory carries its own safety considerations he doesn't mention.

What should you actually know?

The economics argument is real, but it's not the whole story. Both things can be true: funding incentives are broken for unpatentable compounds, and most peptides also lack the human trial data needed to draw firm conclusions about efficacy or safety.

For context, the FDA's Unapproved Drugs Initiative and its 2023 updated guidance on compounded peptides reflect genuine regulatory concern, not just bureaucratic gatekeeping. Several peptides were removed from compounding eligibility specifically because of safety signals in limited data, not because of patent politics. Patients accessing peptides through compounding pharmacies should understand they're operating in a space where quality control, dosing standardization, and long-term safety data are all limited. A 2019 report from the National Academies of Sciences on pharmaceutical compounding flagged contamination risk and dosing variability as real concerns in compounded products. "Not proven unsafe" is not the same as "proven safe." That distinction matters more than any patent argument.